Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
| Autor: | Christopher Bolton, G. Guy, Sarah Al-Izki, C. Stott, Gareth Pryce, Gavin Giovannoni, A. Hilliard, S. Wright |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Article Subject Experimental allergic business.industry Multiple sclerosis Encephalomyelitis Positive control Hindlimb medicine.disease nervous system diseases Surgery body regions chemistry.chemical_compound Baclofen chemistry Anesthesia medicine Spasticity medicine.symptom business Research Article Autoimmune encephalomyelitis |
| Zdroj: | ISRN Neurology |
| ISSN: | 2090-5513 |
| Popis: | This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis was induced in adult ABH mice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control) were injected intravenously and the “stiffness” of limbs assessed by the resistance force against hind limb flexion. Vehicle alone caused no significant change in spasticity. Baclofen (5 mg/kg) induced approximately a 40% peak reduction in spasticity. Sativex dose dependently reduced spasticity; 5 mg/kg THC + 5 mg/kg CBD induced approximately a 20% peak reduction; 10 mg/kg THC + 10 mg/kg CBD produced approximately a 40% peak reduction in spasticity. Sativex has the potential to reduce spasticity in an experimental mouse model of multiple sclerosis (MS). Baclofen reduced spasticity and served as a positive control. Sativex (10 mg/kg) was just as effective as baclofen, providing supportive evidence for Sativex use in the treatment of spasticity in MS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|